Grand Rapids Clinical Oncology Program Grand Rapids

Grand Rapids, MI, United States

Grand Rapids Clinical Oncology Program Grand Rapids

Grand Rapids, MI, United States
SEARCH FILTERS
Time filter
Source Type

Yardley D.,Sarah Cannon Research Institute | Yardley D.,Tennessee Oncology PLLC | Burris III H.,Sarah Cannon Research Institute | Burris III H.,Tennessee Oncology PLLC | And 7 more authors.
Breast Cancer Research and Treatment | Year: 2010

nab-Paclitaxel has shown favorable efficacy and toxicity profiles compared to other taxanes in the treatment of metastatic breast cancer. In this pilot trial, we evaluated a nab-paclitaxel-containing adjuvant regimen in patients with early stage breast cancer. Patients with node-positive or high-risk node-negative early-stage breast cancer were eligible following completion of standard primary therapy. All the patients received four cycles, at 21-day intervals, of nab-paclitaxel (100 mg/m2 IV days 1, 8, and 15) and cyclophosphamide (600 mg/m2 IV day 1). HER2-positive patients also received trastuzumab 8 mg/kg IV on cycle 1 day 1, followed by 6 mg/kg every 21 days for a total of 52 weeks. The purpose of this trial was to evaluate feasibility and toxicity of this nab-paclitaxel-containing adjuvant regimen. 62 patients were treated between 2/08 and 11/08. The majority of the patients (87%) were HER2-negative. This adjuvant regimen was well tolerated, and full doses of all agents were administered in >90% of cycles. Grade 3/4 neutropenia occurred in 53% of the patients; however, only one episode of febrile neutropenia occurred in a total of 249 cycles administered. Other grade 3/4 adverse events occurred in less than 5% of patients. After short follow-up, all the patients remain alive and disease-free. The combination of nab-paclitaxel and cyclophosphamide, with or without trastuzumab, is feasible and well tolerated in patients with early stage breast cancer. Further investigation of the role of nab-paclitaxel in adjuvant breast cancer therapy is indicated, but definitive evaluation will require randomized phase III trials. © 2010 Springer Science+Business Media, LLC.

Loading Grand Rapids Clinical Oncology Program Grand Rapids collaborators
Loading Grand Rapids Clinical Oncology Program Grand Rapids collaborators